Trial Profile
Phase II, Dose-Escalation Study of Pacritinib (SB1518), a novel JAK2-FLT3 inhibitor, with and without combination of 5-Azacytidine, in patients with FLT3-mutated Acute Myeloid Leukemia (AML)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 May 2014
Price :
$35
*
At a glance
- Drugs Pacritinib (Primary) ; Azacitidine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 29 May 2014 New trial record